Successful treatment of a child with MEK inhibitor-induced acneiform eruption with low-dose isotretinoin

Rohit Gupta; Megan F Craddock

doi:10.1111/pde.14959

Successful treatment of a child with MEK inhibitor-induced acneiform eruption with low-dose isotretinoin

Pediatr Dermatol. 2022 Jul;39(4):646-647. doi: 10.1111/pde.14959. Epub 2022 Jul 27.

Authors

Rohit Gupta¹, Megan F Craddock^{2

3}

Affiliations

¹ School of Medicine, Baylor College of Medicine, Houston, Texas, USA.
² Department of Dermatology, Baylor College of Medicine, Houston, Texas, USA.
³ Department of Pediatric Dermatology, Texas Children's Hospital, Houston, Texas, USA.

PMID: 35896172
DOI: 10.1111/pde.14959

Abstract

Selumetinib is a mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor (MEKi) approved to treat inoperable plexiform neurofibromas and used off-label for low-grade gliomas. Acneiform eruptions are a known complication of MEKi use, and in some cases, may lead to paused, dose-reduced, or discontinued therapy. Isotretinoin has been reported as an effective treatment for acneiform eruptions secondary to targeted therapies, primarily in the adult population. Here we describe a pediatric patient with a severe acneiform eruption secondary to selumetinib who was successfully treated with low-dose isotretinoin when unresponsive to conventional therapies.

Keywords: acneiform; isotretinoin; selumetinib.

Publication types

Case Reports

MeSH terms

Acneiform Eruptions* / chemically induced
Acneiform Eruptions* / drug therapy
Child
Humans
Isotretinoin* / therapeutic use
Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors
Neurofibroma, Plexiform*
Protein Kinase Inhibitors* / adverse effects

Substances

Protein Kinase Inhibitors
Mitogen-Activated Protein Kinase Kinases
Isotretinoin